Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2019-02-22
Original SEC Filing: Click here

---

Webplus: SVA/20190222/6-K/2_EX-99.1/000.htm SEC Original: tv514004_ex99-1.htm
Sinovac Determines Trigger Event Occurred Under Rights Agreement · Sinovac Board of Directors Determines Certain Collaborating Shareholders Became Acquiring Persons, Voiding their Preferred Share Purchase Rights; · Valid Preferred Share Purchase Rights Held by all Non-Collaborating Shareholders Exchanged for Common and Preferred Shares; · Board of Directors Amends and Restates Rights Agreement and Declares Dividend Distribution of New Preferred Share

---

---

Webplus: SVA/20190222/6-K/3_EX-99.2/000.htm SEC Original: tv514004_ex99-2.htm
Execution Version TRUST AGREEMENT TRUST AGREEMENT dated as of February 20, 2019 (this “Trust Agreement” or this “Agreement”) between Sinovac Biotech Ltd., as depositor (the “Depositor”), and Wilmington Trust, National Association, a national banking association, as trustee (the “Trustee”). RECITALS WHEREAS, on February 18, 2019, a majority of the board of directors of the Depositor (the “the Board”) determined that

---

---

Webplus: SVA/20190222/6-K/4_EX-99.3/000.htm SEC Original: tv514004_ex99-3.htm
Form of Beneficiary Certification Sinovac Biotech Ltd. CERTIFICATION FOR TRANSFER OF RECORD OWNERSHIP OF 用于转让 SINOVAC BIOTECH LTD.已发行的普通股及 系列优先股登记所有权 以交换此前已存在的权利的证明 年2月22日，Sinovac Biotech Ltd. （“公司”）在《权利协议》（经修订和重新声明，“权利协议”）下的每份先前已存在的权利已在该日期美国市场交易停止时交换（“交换”）为公司普通股0.655股（每股面值0.001美元）（“普通股”）以及公司B系列可转换优先股0.345股（每股面值0.001美元）（“B系列优先股”）。每位股东将收到的全部股份中的普通股将向上调整至最接近的整数股，B系列优先股将向下调整至最接近的整数股。本次交换不适用于2019年2月22日美国市场交易停止时（“交换日期”）由任何收购人士及其任何附属方或关联方所持有的或曾经持有的权利。 2019 1Globe Capital LLC, Chiangjia Li, OrbiMed Advisors LLC and those additional shareholders who voted together with the foregoing at the annual meeting held in February 2018 and their Affiliates and Associates, as such terms are

---

---

Webplus: SVA/20190222/6-K/5_EX-99.4/000.htm SEC Original: tv514004_ex99-4.htm
Form of DTC Participant Certification DTC PARTICIPANT CERTIFICATION FOR TRANSFER OF RECORD OWNERSHIP Capital STOCK OF SHARES OF SINOVAC BIOTECH LTD. On February 18, 2019, the Company’s Board of Directors determined that 1Globe Capital LLC, Chiangjia Li, OrbiMed Advisors LLC, and those additional shareholders who voted together with the foregoing at the annual meeting held in February 2018 and their

---

---

Webplus: SVA/20190222/6-K/6_EX-99.6/000.htm SEC Original: tv514004_ex99-6.htm
SINOVAC BIOTECH LTD. and PACIFIC STOCK TRANSFER COMPANY as Rights Agent Amended and Restated Rights Agreement Dated as of February 22, 2019 AMENDED AND RESTATED RIGHTS AGREEMENT Agreement Company Rights Agent Original Agreement Current Agreement This Amended and Restated Rights Agreement, dated as of February 22, 2019 (this “ RECITALS Original Right Original Record Date Series A Preferred Shares WHEREAS,

---

---

Webplus: SVA/20190222/6-K/7_EX-99.7/000.htm SEC Original: tv514004_ex99-7.htm
CERTIFICATE OF DESIGNATIONS of SERIES C JUNIOR PARTICIPATING PREFERRED SHARES of SINOVAC BIOTECH LTD. Company’s Articles of Incorporation) Company Board of Directors Board SINOVAC BIOTECH LTD., an exempted company incorporated and existing under the laws of Antigua and Barbuda (hereinafter called the “ Preferred Shares Designation and Amount Series C Preferred Shares provided, Section 1. 1 Dividends and Distributions Section

---

---

Webplus: SVA/20190222/6-K/1/000.htm SEC Original: tv514004_6k.htm

---

Company Info:

Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2019-02-22CIK: 0001084201, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
NO. 15 ZHI TONG ROAD,, ZHONGGUANCUN TECH PARK, CHANGPING DISTR.
BEIJING 102200